This compound is a key intermediate in the synthesis of oxazolidinone-class antibiotics, such as Linezolid, used for treating serious Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). The 5-hydroxymethyl group serves as a functional handle for further derivatization in the manufacturing process. Its structure, featuring a 3-fluoro-4-morpholinophenyl substituent, contributes to the antibacterial potency and selectivity of the final drug by targeting bacterial protein synthesis at the ribosome.

Additionally, derivatives of this oxazolidinone scaffold are investigated for broader antimicrobial applications, potential immunomodulatory effects, and uses in oncology or autoimmune disease research due to their unique binding properties.